Look no further than GlaxoSmithKline shedding its consumer health arm to form Haleon ... more than just logo, font, or colour palette: brand represents everything a business says and does ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of ...

Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare ...

The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

in Haleon (HLN.L), opens new tab, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday. The sale of 700 million Haleon ...

Marcum Wealth LLC raised its holdings in shares of Haleon plc (NYSE:HLN – Free Report) by 19.7% in the fourth quarter, ...

Morgan Stanley downgraded shares of Haleon (NYSE:HLN – Free Report) from an overweight rating to an equal weight rating in a ...

Shares of Haleon PLC HLN inched up 0.97% to £3.73 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.

Pfizer will sell shares worth £2.50 billion ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer will sell shares worth £2.50 billion (€2.96 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan has said.